Mao JJ, Pillai GG, Andrade CJ, Ligibel JA, Basu P, Cohen L, Khan IA, Mustian KM, Puthiyedath R, Dhiman KS, Lao L. Integrative oncology: Addressing the global challenges of cancer prevention and treatment. CA: A Cancer Journal for Clinicians. 2022;72(2):144 – 64.

Mani K, Deng D, Lin C, Wang M, Hsu ML, Zaorsky NG. Causes of death among people living with metastatic cancer. Nat Commun. 2024;15(1):1519.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartz SM. Epidemiology of cancer. Clin Chem. 2024;70(1):140–9.

Article  PubMed  Google Scholar 

Bizuayehu HM, Ahmed KY, Kibret GD, Dadi AF, Belachew SA, Bagade T, Tegegne TK, Venchiarutti RL, Kibret KT, Hailegebireal AH, Assefa Y. Global disparities of cancer and its projected burden in 2050. JAMA network open. 2024;7(11):e2443198.

Article  PubMed  PubMed Central  Google Scholar 

de la Fuente-Nunez C, Cesaro A, Hancock RE. Antibiotic failure: beyond antimicrobial resistance. Drug Resist Updates. 2023 Oct;18:101012.

Carr A, Mackie NE, Paredes R, Ruxrungtham K. HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective. Antivir Ther. 2023;28(5):13596535231201162.

Gillet JP, Gottesman MM. 2010. Mechanisms of multidrug resistance in cancer. Multi-drug Resist cancer, pp.47–76.

Gabaldón T. Nothing makes sense in drug resistance except in the light of evolution. Curr Opin Microbiol. 2023;75:102350.

Article  PubMed  Google Scholar 

Corjan V, Sardari V. The role and mechanisms of action of microRNAs in cancer. InCercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 (pp. 50–50).

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769–92.

Fessart D, Robert J. Mechanisms of cancer drug resistance. Bull Du Cancer 2023 Sep 5:S0007–4551.

Levantini E, Maroni G, Del Re M, Tenen DG. April. EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology. Academic; 2022.

Google Scholar 

Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu Y. Drug-metabolizing cytochrome P450 enzymes have multifarious influences on treatment outcomes. Clin Pharmacokinet. 2021;60:585–601.

Article  CAS  PubMed  Google Scholar 

El-Sayes N, Vito A, Mossman K. 2021. Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers, 13(4), p.806.

Cheng YQ, Wang SB, Liu JH, Jin L, Liu Y, Li CY, Su YR, Liu YR, Sang X, Wan Q, Liu C. Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours. Cell Prolif. 2020;53(8):e12865.

Article  PubMed  PubMed Central  Google Scholar 

Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013;32:623–42.

Article  CAS  PubMed  Google Scholar 

Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–92.

Article  CAS  PubMed  Google Scholar 

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769–92.

Article  PubMed  PubMed Central  Google Scholar 

Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 2016;8(4):a019521.

Article  PubMed  PubMed Central  Google Scholar 

Cooper WA, Lam DC, O’Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Disease. 2013;5(Suppl 5):S479.

Google Scholar 

Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, Hayashi N, Sohn J, De Sousa RT, Brufsky AM, O’Brien CS. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO open. 2023;8(4):101615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rotow JK, Lee JK, Madison RW, Oxnard GR, Jänne PA, Schrock AB. Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib. J Thorac Oncol. 2024;19(2):227–39.

Article  CAS  PubMed  Google Scholar 

Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643–9.

Article  CAS  PubMed  Google Scholar 

Mahapatra S, Jonniya NA, Koirala S, Ursal KD, Kar P. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention. J Biomol Struct Dynamics. 2023;41(22):13509–33.

Article  CAS  Google Scholar 

Handsaker RE, Van Doren V, Berman JR, Genovese G, Kashin S, Boettger LM, McCarroll SA. Large multiallelic copy number variations in humans. Nat Genet. 2015;47(3):296–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaissière T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Research/Reviews Mutat Res. 2008;659(1–2):40–8.

Article  Google Scholar 

Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(3):245–54.

Article  CAS  PubMed  Google Scholar 

Šimoničová K, Janotka Ľ, Kavcová H, Sulová Z, Breier A, Messingerova L. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resist Updat. 2022;61:100805. https://doi.org/10.1016/j.drup.2022.100805. Epub 2022 Jan 21. PMID: 35227933.

Article  CAS  PubMed  Google Scholar 

Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002;123(6):1804–11.

Article  CAS  PubMed  Google Scholar 

Li K, Luo H, Huang L, Luo H, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20:1–3.

PubMed  PubMed Central  Google Scholar 

Cervantes B, André T, Cohen R. Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions. Therapeutic Adv Med Oncol. 2024;16:17588359231170473.

Article  Google Scholar 

Lande R. 1979. Effective deme sizes during long-term evolution estimated from rates of chromosomal rearrangement. Evolution, pp.234–51.

Neckles C, Rajan S, S. and, Caplen NJ. Fusion transcripts: unexploited vulnerabilities in cancer? Wiley Interdisciplinary Reviews: RNA. 2020;11(1):e1562.

Desai A, Lovly CM. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Translational Lung Cancer Res. 2023;12(3):615.

Article  CAS  Google Scholar 

Peters S, Zimmermann S. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. Curr Treat Options Oncol. 2018;19(7):37.

Article  PubMed  Google Scholar 

Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med. 2003;3(7):589–96.

Article  CAS  PubMed  Google Scholar 

DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. Cancer J Clin. 2014;64(4):252–71.

Article  Google Scholar 

Wang ZH, Zheng ZQ, Jia SC, Liu SN, Xiao XF, Chen GY, Liang WQ, Lu XF. Trastuzumab resistance in HER2-positive breast cancer: mechanisms, emerging biomarkers and targeting agents. Front Oncol. 2022;12:1006429.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadida HQ, Abdulla A, Al Marzooqi S, Hashem S, Macha MA, Akil AS, Bhat AA. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Translational Oncol. 2024;39:101821.

Article  CAS  Google Scholar 

Asano T. Drug Resistance in Cancer Therapy and the role of Epigenetics. J Nippon Med Sch. 2020;87(5):244–51.